ERA 2025 Highlights Podcast

Presented by

Dr. Rachel Giles, Robert van den Heuvel, Medicom

Conference

ERA 2025

In this podcast (10:19), Medicom’s correspondents discuss 6 presentations that were held at the 62nd Annual Meeting of the European Renal Association, held recently in Vienna:

CANVAS trial showed that canagliflozin 300 mg reduced major cardiovascular events and all-cause mortality in type 2 diabetes; 100 mg did not.

Empagliflozin meta-analysis on kidney disease progression slowed eGFR decline by 64% and reduced kidney disease progression risk by 30%, with stronger effects in patients with diabetes.

CONFIDENCE trial: The combination of finerenone + empagliflozin in CKD and type 2 diabetes reduced albuminuria by 52% at 180 days, outperforming monotherapy.

Acute eGFR dip and AKI risk with empagliflozin was not linked to higher risk of acute kidney injury; empagliflozin reduced AKI events by 27%.

ERA registry data on kidney transplantation survival benefit revealed that standard criteria donor transplants conferred a survival benefit over dialysis, regardless of recipient age or comorbidities; expanded criteria did not.

VISIONARY trial: sibeprenlimab in IgA nephropathy reduced urinary protein/creatinine ratio by 51.2% over 9 months with a reassuring safety profile.

Medical Conferences

Table of Contents: ERA 2025

Featured articles

Letter from the Editor

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

ERA 2025 Highlights Podcast

New Frontiers in Cardiorenal Protection: SGLT2 Inhibitors and Emerging Therapies

Acute eGFR dip following empagliflozin initiation is not associated with acute kidney injury

Sibeprenlimab is an emerging treatment option for IgA nephropathy

Finerenone plus empagliflozin as a new potential combination in patients with type 2 diabetes and chronic kidney disease

Large meta-analysis shows that empagliflozin slows kidney progression and reduces risk among patients with multiple diseases

Canagliflozin has a dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes

Late-Breaking Nephrology Studies

Survival benefit from kidney transplantation depends on the donor source

Mineral receptor antagonists are not beneficial for patients undergoing dialysis

Spironolactone is not useful in dialysis with cardiovascular risk

Factor XI inhibition is not useful for end-stage kidney disease patients receiving haemodialysis

ERA’s Top 10 Abstracts

Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time

NefIgArd: Nefecon leads to sustained decline in proteinuria and eGFR stabilisation

Immune checkpoint inhibitor-induced acute interstitial nephritis characterised by distinct immunophenotypes with potentially different management

Pegcetacoplan is a treatment option for patients with C3G or IC-MPGN with nephrotic-range proteinuria

Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy

Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome

Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1

Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Pegcetacoplan is a treatment option for adolescents with C3G or IC-MPGN

Clinical Outcomes in Transplant and Genetic Kidney Diseases

Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality

Diabetes leads to negative mortality outcomes in kidney transplant patients

Emerging Pathophysiological Mechanisms and Therapeutic Targets

NPT2b could be a new therapeutic target for kidney diseases based on preclinical data

Inhibition of the cGAS/STING pathway has the potential to aid kidney recovery in chronic granulomatous disease